| Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C S Petta, C Cammā, C Scazzone, C Tripodo, V Di Marco, A Bono, D Cabibi, ... Hepatology 51 (4), 1158-1167, 2010 | 519 | 2010 |
| Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease P Dongiovanni, S Petta, C Maglio, AL Fracanzani, R Pipitone, E Mozzi, ... Hepatology 61 (2), 506-514, 2015 | 346 | 2015 |
| Field‐practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy M Iavarone, G Cabibbo, F Piscaglia, C Zavaglia, A Grieco, E Villa, ... Hepatology 54 (6), 2055-2063, 2011 | 340 | 2011 |
| The long‐term course of chronic hepatitis B V Di Marco, OL Iacono, C Cammā, A Vaccaro, M Giunta, G Martorana, ... Hepatology 30 (1), 257-264, 1999 | 326 | 1999 |
| Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine DV Di Marco, A Marzano, P Lampertico, P Andreone, T Santantonio, ... Hepatology 40 (4), 883-891, 2004 | 310 | 2004 |
| Prophylaxis and treatment of hepatitis B in immunocompromised patients A Marzano, E Angelucci, P Andreone, M Brunetto, R Bruno, P Burra, ... Digestive and Liver Disease 39 (5), 397-408, 2007 | 262 | 2007 |
| Hepatitis C viremia in chronic liver disease: relationship to interferon‐α or corticosteroid treatment S Magrin, A Craxi, C Fabiano, RG Simonetti, G Fiorentino, L Marino, ... Hepatology 19 (2), 273-279, 1994 | 257 | 1994 |
| Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C L Rizzo, V Calvaruso, B Cacopardo, N Alessi, M Attanasio, S Petta, ... American Journal of Gastroenterology 106 (12), 2112-2120, 2011 | 243 | 2011 |
| SAFE biopsy: a validated method for large‐scale staging of liver fibrosis in chronic hepatitis C G Sebastiani, P Halfon, L Castera, S Pol, DL Thomas, A Mangia, ... Hepatology 49 (6), 1821-1827, 2009 | 215 | 2009 |
| Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C C Camma, S Bruno, V Di Marco, D Di Bona, M Rumi, M Vinci, C Rebucci, ... Hepatology 43 (1), 64-71, 2006 | 202 | 2006 |
| Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication AJ van der Meer, JJ Feld, H Hofer, PL Almasio, V Calvaruso, ... Journal of hepatology 66 (3), 485-493, 2017 | 189 | 2017 |
| Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection S Petta, C Camma, V Di Marco, N Alessi, D Cabibi, R Caldarella, A Licata, ... American Journal of Gastroenterology 103 (5), 1136-1144, 2008 | 189 | 2008 |
| Interferon‐α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response L Pagliaro, A Craxí, C Cammaá, F Tiné, V Di Marco, OL Iacono, P Almasio Hepatology 19 (4), 820-828, 1994 | 165 | 1994 |
| Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents V Calvaruso, G Cabibbo, I Cacciola, S Petta, S Madonia, A Bellia, F Tinč, ... Gastroenterology 155 (2), 411-421. e4, 2018 | 155 | 2018 |
| The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease S Petta, M Maida, FS Macaluso, V Di Marco, C Camma, D Cabibi, A Craxė Hepatology 62 (4), 1101-1110, 2015 | 153 | 2015 |
| Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation … S Petta, VWS Wong, C Cammā, JB Hiriart, GLH Wong, F Marra, J Vergniol, ... Hepatology 65 (4), 1145-1155, 2017 | 146 | 2017 |
| Cost‐effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C C Cammā, S Petta, M Enea, R Bruno, F Bronte, V Capursi, A Cicchetti, ... Hepatology 56 (3), 850-860, 2012 | 145 | 2012 |
| Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial P Caraceni, O Riggio, P Angeli, C Alessandria, S Neri, FG Foschi, ... The Lancet 391 (10138), 2417-2429, 2018 | 144 | 2018 |
| Hyperuricemia is associated with histological liver damage in patients with non‐alcoholic fatty liver disease S Petta, C Cammā, D Cabibi, V Di Marco, A Craxė Alimentary pharmacology & therapeutics 34 (7), 757-766, 2011 | 143 | 2011 |
| Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index S Petta, V Di Marco, C Cammā, G Butera, D Cabibi, A Craxi Alimentary pharmacology & therapeutics 33 (12), 1350-1360, 2011 | 140 | 2011 |
